Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation - PubMed (original) (raw)
. 2006 Nov 15;108(10):3548-55.
doi: 10.1182/blood-2005-12-013748. Epub 2006 Jul 27.
E Joanna Baxter, Philip A Beer, Linda M Scott, Anthony J Bench, Brian J P Huntly, Wendy N Erber, Rajko Kusec, Thomas Stauffer Larsen, Stéphane Giraudier, Marie-Caroline Le Bousse-Kerdilès, Martin Griesshammer, John T Reilly, Betty Y Cheung, Claire N Harrison, Anthony R Green
Affiliations
- PMID: 16873677
- DOI: 10.1182/blood-2005-12-013748
Free article
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J Campbell et al. Blood. 2006.
Free article
Abstract
The identification of an acquired mutation of JAK2 in patients with myeloproliferative disorders has raised questions about the relationship between mutation-positive and mutation-negative subtypes, timing of the JAK2 mutation, and molecular mechanisms of disease progression. Here we demonstrate that patients with V617F(-) essential thrombocythemia do not commonly progress to become V617F(+). Consistent with the concept of distinct pathogenetic mechanisms, we show that patients with and without the JAK2 mutation have different patterns of cytogenetic abnormality, with virtually all patients carrying the 20q deletion or trisomy 9 being V617F(+). We also investigated the existence of a "pre-JAK2" phase by comparing the proportion of clonally derived granulocytes, estimated from X-chromosome inactivation patterns (XCIPs), with the proportion of V617F(+) granulocytes. Our results demonstrate that inherent XCIP variability between granulocytes and T cells produces a systematically biased pattern of results that may be misinterpreted as evidence for an excess of clonally derived granulocytes, an observation that limits the utility of XCIP analysis in this context. Lastly, we studied 4 patients with V617F(+) myeloproliferative disorders who subsequently developed acute myeloid leukemia. In 3 patients the leukemic cells were V617F(-), suggesting that in these patients the leukemia arose in a V617F(-) cell.
Similar articles
- Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC. Theocharides A, et al. Blood. 2007 Jul 1;110(1):375-9. doi: 10.1182/blood-2006-12-062125. Epub 2007 Mar 15. Blood. 2007. PMID: 17363731 - JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M. Rumi E, et al. Cancer. 2006 Nov 1;107(9):2206-11. doi: 10.1002/cncr.22240. Cancer. 2006. PMID: 16998940 - What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R, Ribeiro P, Lourenço A, Santos SC, Santos M, Costa I, de Sousa AB. Lopes da Silva R, et al. Lab Hematol. 2011 Mar;17(1):12-6. doi: 10.1532/LH96.10018. Lab Hematol. 2011. PMID: 21421540 - JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO. Hexner EO. Curr Opin Hematol. 2007 Sep;14(5):450-4. doi: 10.1097/MOH.0b013e3282861d1b. Curr Opin Hematol. 2007. PMID: 17934351 Review.
Cited by
- Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O'Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I, Mead AJ. Rodriguez-Meira A, et al. Nat Genet. 2023 Sep;55(9):1531-1541. doi: 10.1038/s41588-023-01480-1. Epub 2023 Sep 4. Nat Genet. 2023. PMID: 37666991 Free PMC article. - Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC, Agosto-Peña J. Yang FC, et al. Int J Hematol. 2023 Jun;117(6):791-806. doi: 10.1007/s12185-023-03586-y. Epub 2023 Apr 16. Int J Hematol. 2023. PMID: 37062051 Review. - Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.
Rontauroli S, Carretta C, Parenti S, Bertesi M, Manfredini R. Rontauroli S, et al. Int J Mol Sci. 2022 Dec 3;23(23):15256. doi: 10.3390/ijms232315256. Int J Mol Sci. 2022. PMID: 36499582 Free PMC article. Review. - Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.
Brune MM, Rau A, Overkamp M, Flaadt T, Bonzheim I, Schürch CM, Federmann B, Dirnhofer S, Fend F, Tzankov A. Brune MM, et al. Cancers (Basel). 2021 Nov 9;13(22):5605. doi: 10.3390/cancers13225605. Cancers (Basel). 2021. PMID: 34830756 Free PMC article. - Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E, Gil C, Aguiar E, Bergua J, López-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodríguez-Medina C, López-Pavía M, Tormo M, Algarra L, Amigo ML, Sayas MJ, Labrador J, Rodríguez-Gutiérrez JI, Benavente C, Costilla-Barriga L, García-Boyero R, Lavilla-Rubira E, Vives S, Herrera P, García-Belmonte D, Herráez MM, Vasconcelos Esteves G, Gómez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MÁ, Montesinos P. Martínez-Cuadrón D, et al. Blood Adv. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. Blood Adv. 2022. PMID: 34794172 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous